Skip to content

COMPASS Pathways plc

British biotechnology company developing psilocybin-based treatments for mental health disorders

CMPS Nasdaq SEC CIK 1816590

Follow COMPASS Pathways Weekly email: filings, results, news

News

7 stories filed under COMPASS Pathways

Markets

Thread · 4 stories

Compass Pathways: Still A Buy, But The Exit Just Got Complicated

Markets 30 d ago also on COMP

From Valley of Despair to FDA Threshold: The Turnaround of COMPASS Pathways (CMPS)

Markets 38 d ago also on COMP

COMPASS Pathways at Canaccord Genuity conference: launch path in focus

Markets 43 d ago also on COMP

Shrooms, Inc.: Why CMPS Could Be 2027’s Wildest Biotech Bet

Markets 44 d ago

Policy

Thread · 2 stories

COMPASS Pathways at TD Cowen summit: launch prep meets regulatory risk

Policy 1 d ago 2 sources also on TD COMP

Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization

Policy 30 d ago also on COMP

More coverage

Oppenheimer reiterates Compass Pathways stock rating on FDA progress

Markets 50 d ago 2 sources also on OPY COMP

Profile

Headquarters: CHESIRE
Founded: 2016
Sector: Healthcare
Industry: Pharmaceutical Preparations
Website: compasspathways.com

Peers

Where this page comes from

Profile · SEC EDGAR, Wikidata

News · 7 stories clustered from the RSS aggregator